If you want to search Cost Curve back issues or link to anything you read here, the web links and archive are online at costcurve.beehiiv.com. You can subscribe there, too.
Last week, I gave four reasons why I was happy to be skipping J.P. Morgan this year. I should have given a fifth: 90% of the dialogue around #JPM25 --
Everyone seems to accept that we’re going to get the announcement of the next 15 medicines up for Medicare price controls before Biden leaves office, which means there are only
This new white paper from BRG is an incredible resource. It breaks down exactly where the money goes in the pharmaceutical supply chain with a lot of precision, and it
It’s the New Year. It’s a time to refresh and reflect and reconnect. In that spirit, I have two asks of you: First: If you find the newsletter useful, please
If you want to search Cost Curve back issues or link to anything you read here, the web links and archive are online at costcurve.beehiiv.com. You can subscribe there, too.
If you want to search Cost Curve back issues or link to anything you read here, the web links and archive are online at costcurve.beehiiv.com. You can subscribe there, too.
In the newsletter earlier today, I mentioned that I was looking for your collective wisdom on how to handle 2025. The link to the survey is now live, and I
It’s a super-slow news day today**, which is not particularly unexpected given the worldwide pause to flip the calendar. I have a handful of links to share below, but --
Yesterday, I misstated the companies involved in the Sagebrush/HRSA 340B lawsuit. The plaintiffs in that case are Amgen, Lilly, and UCB. I’ve fixed yesterday’s post online but wanted to correct